Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06238765 · ClinicalTrials.gov registry record
CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
A clinical trial of Atopic Dermatitis, sponsored by CorEvitas.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT06238765: Recruiting study of Atopic Dermatitis, sponsored by CorEvitas.
NCT06238765 is a study of Atopic Dermatitis that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 1,500 participants, above the 599-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (150% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06238765, a study of Atopic Dermatitis, is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.
Primary Outcome
The major clinical outcomes include an assessment of the epidemiology of Atopic Dermatitis; to better understand the presentation, natural history, management and outcomes.
Conditions Studied
Study Locations (1)
Massachusetts
- CorEvitas, LLC - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2023-12-02 |
| Est. Completion | 2099-12-31 |
What NCT06238765 shows while recruiting
NCT06238765 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 599-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (150% higher).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions.
NCT06238765 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06238765 about?
NCT06238765 is a clinical study titled "CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry". Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.
What is the current status of trial NCT06238765?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2023-12-02. Estimated completion is 2099-12-31.
What conditions does trial NCT06238765 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
Who is sponsoring clinical trial NCT06238765?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06238765 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06238765's enrollment target sits among peer trials
1,500 10th of 150 higher than 141 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI